Navigation Links
Percutaneous aortic valve replacement safe, successful in high-risk patients

Catheter techniques are expanding into new territory, successfully aiding in the replacement of narrowed, calcified aortic valves in patients too sick to withstand open-chest surgery. According to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9?2, 2007, in Orlando, FL, patients who were treated with the CoreValve Revalving System (CoreValve, Irvine, CA) experienced improvements in both the size of the aortic valve and in the severity of heart failure.

To evaluate the CoreValve system, Anita Asgar, M.D., and her colleagues at Montreal Heart Institute recruited 17 elderly patients with a severely narrowed aortic valve, all of whom had been turned down for surgery because of other health problems. In severe narrowing, or stenosis, of the aortic valve, the heart has difficulty pumping blood from the left ventricle to the rest of the body. The result is a back-up of fluid into the lungs and severe shortness of breath with even minimal activity.

With the CoreValve system, aortic valve replacement is performed by threading a special delivery catheter through the femoral artery in the groin and into the aorta in a direction opposite, or retrograde, to the normal flow of blood. Once the catheter is properly positioned in the opening of the aortic valve, it is pulled back to release the CoreValve, a self-expanding stent-like frame with the new tissue valve attached to its core. As it expands, the CoreValve covers the diseased natural valve leaflets.

During the procedure, the patients were placed on a bypass pump for an average of 30?0 minutes to minimize blood flow through the aorta and ease placement of the replacement valve.

All 17 patients survived the procedure. One patient died 5 days later from stroke. Five additional patients died after discharge from the hospital from health problems unrelated to the replacement valve. Follow-up in the 11 survi vors showed that the average aortic valve area more than doubled, on average, following the procedure. In addition, the severity of heart failure significantly improved, as gauged by both B-type natriuretic peptide (NT-BNP), a protein produced by the ventricles of the heart during heart failure, and New York Heart Association (NHYA) classification. After the procedure, patients were ranked in NYHA class II, on average, suggesting most were able to engage in a moderate level of activity before becoming short of breath.
'"/>

Source:Society for Cardiovascular Angiography and Interventions


Related biology news :

1. Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host.
2. Bone and cartilage growth to blame for heart valve disease
3. Findings advance use of adult stem cells for replacement bone
4. Genes may determine success of hip replacement surgery
5. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
6. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
7. New, automated tool successfully classifies and relates proteins in unprecedented way
8. Biomarkers isolated from saliva successfully predict oral and breast cancer
9. UN successfully tests green pesticide against locusts
10. Stem cell therapy successfully treats heart attack in animals
11. Mad cow proteins successfully detected in blood

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
(Date:1/6/2016)... Calif. , Jan. 6, 2016  Varam Capital, ... as their trusted partner to deliver advanced authentication solutions ... financial services to the poor. A loan of a ... their lives, giving them the ability to purchase livestock ... to make clothing, or stock for a local store. ...
(Date:1/6/2016)...   A&D Medical , a global leader in ... be unveiling a new line of personal mobile health ... UltraConnect – at CES 2016, with the introduction of its ... monitors. ... upper arm wireless blood pressure monitors represent the launch ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Investor Conference 2016, to be held February 8-9, ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, taking ... February 10-11, 2016. James Sapirstein , Chief ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
(Date:2/4/2016)... , February 4, 2016 Strasbourg, ... (ABL), Inc. --> Strasbourg, France , ... --> PharmaVentures is pleased to announce that it acted ... biopharmaceutical manufacturing unit in Strasbourg, France , ... --> --> Transgene (Euronext: TNG), ...
Breaking Biology Technology: